Full Press Release Details
Australian Stock Exchange
Company Announcements Office
Level 4, Exchange Centre
Annual General Meeting
That, for the purposes of section 250R(2) of the Corporations Act 2001 (Cth) and for all other purposes, the 2012 Remuneration Report as published in the Directors Report of the Annual
Financial Report of the Company for the year ended 30 June 2012 be adopted.
This resolution was passed unanimously
That, Mr Albert Yue-Ling Wong, a director of the Company, who retires in accordance with the Company s Constitution and, being eligible, offers himself for re-election, be re-elected as a
director of the Company.
This resolution was passed unanimously by a show of hands.
That, in accordance with ASX Listing Rule 10.14 and section 208 of the Corporations Act and for all other purposes, approval is
given for the Company to issue 1,200,000 Options to Matthew Lehman pursuant to the Company s Global Employee Share Option Plan and on the terms and conditions set out in the Explanatory Notes accompanying the Notice.
This resolution was passed unanimously by a show of hands.
That for the purposes of Exception 9(b) of ASX Listing
Rule 7.2 and for all other purposes, approval is given for the issue of performance rights and/or options to, or for the benefit of, employees of the Company under the Company s Executive Incentive Plan, the terms of which are summarised in the
This resolution was passed unanimously by a show of hands.
BioMed Ltd, Level 7, 151 Macquarie Street NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 9276 1284
In accordance with Section 251AA of the Corporations Act, the following information is provided to the
Australian Stock Exchange Limited for the proxy votes received for each resolution passed by members of Prima BioMed Ltd at the Annual General Meeting held on 16 November 2012:
| Resolution | Proxy For | Proxy Against | Proxy Discretion | Proxy Abstain/Exclusion | ||||||||||
| Number of shares | % of Proxy of shares | Number Of shares | % of Proxy of shares | Number of shares | % of Proxy of shares | Number of shares | ||||||||
| Remuneration Report adoption | 52,970,393 | 78.98% | 13,925,328 | 20.76% | 172,544 | 0.26% | 52,793,833 | |||||||
| Re-election of Mr Albert Wong | 99,555,464 | 85.26% | 8,520,741 | 7.30% | 8,693,334 | 7.44% | 3,092,549 | |||||||
| Approval of the issue of 1,200,000 options to Mr Matthew Lehman. | 87,848,540 | 75.36% | 20,175,099 | 17.31% | 8,547,286 | 7.33% | 3,291,163 | |||||||
| Approval of the Company s Executive Incentive Plan | 80,870,317 | 68.92% | 27,919,637 | 23.80% | 8,537,286 | 7.28% | 2,534,848 |
BioMed Ltd, Level 7, 151 Macquarie Street NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 9276 1284